{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:11:46Z","timestamp":1781788306727,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR06593"],"award-info":[{"award-number":["R01AR06593"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ymgmr.2021.100798","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T19:01:19Z","timestamp":1630177279000},"page":"100798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Nathaniel","family":"Kleytman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagishwari","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgmr.2021.100798_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100798_bb0010","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","year":"2010"},{"issue":"21","key":"10.1016\/j.ymgmr.2021.100798_bb0015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100798_bb0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metab"},{"issue":"9041","key":"10.1016\/j.ymgmr.2021.100798_bb0025","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(96)04451-0","article-title":"Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher\u2019s disease","volume":"348","author":"Mistry","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100798_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","article-title":"Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues","volume":"39","author":"Xu","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgmr.2021.100798_bb0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF03401556","article-title":"Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages","volume":"1","author":"Beutler","year":"1995","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100798_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100798_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"9985","key":"10.1016\/j.ymgmr.2021.100798_bb0050","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ymgmr.2021.100798_bb0055","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ymgmr.2021.100798_bb0060","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/ajh.25875","article-title":"Real-world effectiveness of eliglustat in treatment-na\u00efve and switch patients enrolled in the international collaborative Gaucher group Gaucher registry","volume":"95","author":"Mistry","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"4 Suppl 5","key":"10.1016\/j.ymgmr.2021.100798_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"16","key":"10.1016\/j.ymgmr.2021.100798_bb0070","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","article-title":"Gaucher disease: recommendations on diagnosis, evaluation, and monitoring","volume":"158","author":"Charrow","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgmr.2021.100798_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2016.12.002","article-title":"Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease","volume":"68","author":"Murugesan","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"40","key":"10.1016\/j.ymgmr.2021.100798_bb0080","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene: nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100798_bb0085","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"9985","key":"10.1016\/j.ymgmr.2021.100798_bb0090","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(15)60206-9","article-title":"Eliglustat for Gaucher\u2019s disease: trippingly on the tongue","volume":"385","author":"Hughes","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100798_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"457","key":"10.1016\/j.ymgmr.2021.100798_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1651-2227.2008.00653.x","article-title":"Gaucher disease: unmet treatment needs","volume":"97","author":"Mehta","year":"2008","journal-title":"Acta Paediatr."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100798_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.ymgmr.2021.100798_bb0110","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100798_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bcmd.2002.0511","article-title":"Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients","volume":"28","author":"Poll","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100798_bb0120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100798_bb0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.ymgmr.2021.100798_bb0130","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/2211-5463.12078","article-title":"Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 gaucher disease patients and mouse models","volume":"6","author":"Kramer","year":"2016","journal-title":"FEBS Open Bio."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100798_bb0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100798_bb0140","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135 years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"45","key":"10.1016\/j.ymgmr.2021.100798_bb0145","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.ymgmr.2021.100798_bb0150","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ymgmr.2021.100798_bb0155","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:54:55Z","timestamp":1778860495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"alternative-id":["S2214426921000926"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100798","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100798"}}